Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

red in accordance with US GAAP.

Where applicable the following items, including their tax effect, have been excluded from both 2011 and 2010 Non GAAP earnings, and from our 2011 Outlook:

Amortization and asset impairments:

  • Intangible asset amortization and impairment charges; and
  • Other than temporary impairment of investments.


 

Acquisitions and integration activities:

  • Upfront payments and milestones in respect of in-licensed and acquired products;
  • Costs associated with acquisitions, including transaction costs, fair value adjustments on contingent consideration and acquired inventory;
  • Costs associated with the integration of companies; and
  • Noncontrolling interests in consolidated variable interest entities.


 

Divestments, re-organizations and discontinued operations:

  • Gains and losses on the sale of non-core assets;
  • Costs associated with restructuring and re-organization activities;
  • Termination costs; and
  • Income/(losses) from discontinued operations.

Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US GAAP results, has been separately disclosed for the presentation of 2010 and 2011 Non GAAP earnings.

Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, tax and interest payments.

Free cashflow represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, but including capital expenditure in the ordinary course of business.

A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented on pages 19 to 23.


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... (PRWEB) September 20, 2014 ... urological and interventional radiology products and services, has ... subsidiary with Clinicon Corporation for its ... HealthTronics’ portfolio of minimally invasive, mobile, surgical technology—offering ... , Under the agreement, HealthTronics will make available ...
(Date:9/19/2014)... yields to disease risks, the biological characteristics people care ... as for heightthe textbook example of a complex traitattributes ... by multiple genetic and environmental influences, making it challenging ... genes, geneticists typically mate two individuals that differ in ... mouseand then study their descendents, looking for genes that ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Nanotechnology and its potential to revolutionize the ... government agencies, multinational corporations and small start-ups. The ... government funded research projects largely due to the ... capital investments. Government budgets earmarked for this evolving ...
(Date:9/19/2014)...  Nektar Therapeutics (NASDAQ: NKTR ) ... analgesic profiles of a series of the company,s ... The preclinical research candidates were created using Nektar,s ... The analgesic properties of kappa receptor agonism are ... Kappa opioid receptors are expressed in the peripheral ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... In eCTD Migration And Submissions Outsourcing And, Provides Insights Into ... ... And Europe, PHILADELPHIA and LONDON, July 17 The Scientific,business ... Regulatory Affairs Trends Survey. The survey attracted respondents,from across the globe ...
... Holdings, Inc. and its,operating subsidiary, US Oncology, Inc., ... August 7, 2008., A conference call and ... for the company,s bondholders following the distribution of ... Oncology,s management,team will discuss the financial results. Further ...
... TORONTO, July 16 /PRNewswire/ - Eugene Melnyk and ... see a number of incomplete or,inaccurate statements in ... "The hallmark of this proxy contest to date ... see the Board and management using the,same tactics," ...
Cached Biology Technology:The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 2The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 3
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... of researchers from McGill University and the Quebec ... polyethylene ,microbeads, Canadian Journal of Fisheries and ... from cosmetics, household cleansers, or industrial cleansers, to ... to their small size and buoyancy, they may ... are a global contaminant in the world,s oceans, ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... Troy, N.Y. The purification of drug components is ... particularly true of drugs that utilize proteins, which are ... Scientists within the Center for Biotechnology and Interdisciplinary Studies ... resonance (NMR) to understand and improve an important protein ...
... to anchor teeth back in the jaw using stem cells ... the first time by researchers at the University of Illinois ... advance in the battle against gum disease, a serious infection ... U.S. adults suffer from gum disease, according to the National ...
... recent human trials for a promising new class of ... without shutting down the immune system, some of the ... In response, an interdisciplinary team of Florida State ... genetic screening method that can identify the drug-resistant HCV ...
Cached Biology News:Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3Technique to reattach teeth using stem cells developed at UIC 2Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
Kinase Buffer can be used to assay protein kinase activity...
Biology Products: